Objective. Fcc receptor IIb (FccRIIb) is an essential negative regulator of B cells that blocks B cell receptor (BCR) signaling and triggers c-Abl-dependent apoptosis of B cells. FccRIIb-deficient mice display splenomegaly with expansion of B cells, leading to lupus. FccRIIb-I232T is a hypofunctional polymorphism associated with lupus susceptibility in humans, an autoimmune disease linked to diminished deletion of autoreactive B cells. In the context of the FccRIIb-I232T polymorphism, we investigated the role of FccRIIb in the deletion of lowaffinity germinal center (GC) B cells, an important mechanism for preventing autoimmunity.
Objective. Fcc receptor IIb (FccRIIb) is an essential negative regulator of B cells that blocks B cell receptor (BCR) signaling and triggers c-Abl-dependent apoptosis of B cells. FccRIIb-deficient mice display splenomegaly with expansion of B cells, leading to lupus. FccRIIb-I232T is a hypofunctional polymorphism associated with lupus susceptibility in humans, an autoimmune disease linked to diminished deletion of autoreactive B cells. In the context of the FccRIIb-I232T polymorphism, we investigated the role of FccRIIb in the deletion of lowaffinity germinal center (GC) B cells, an important mechanism for preventing autoimmunity.
Methods. We generated FccRIIb 232T/T mice to mimic human FccRIIb-I232T carriers and immunized mice with chicken gamma globulin (CGG)-conjugated NP, a T celldependent antigen, to examine the response of GC B cells.
Results. Compared to wild-type (WT) mice, FccRIIb 232T/T mice showed increased numbers of low-affinity NP-specific IgG and NP-specific B cells and plasma cells; additionally, the expression of a somatic mutation (W33L) in their V H 186.2 genes encoding high-affinity BCR was reduced. Notably, FccRIIb 232T/T mice had a higher number of GC light zone B cells and showed less apoptosis than WT mice, despite having equivalent follicular helper T cell numbers and function. Moreover, phosphorylation of c-Abl was reduced in FccRIIb 232T/T mice, and treatment of WT mice with the c-Abl inhibitor nilotinib during the peak of GC response resulted in reduced affinity maturation reminiscent of FccRIIb 232T/T mice.
Conclusion.
Our findings provide evidence of a critical role of FccRIIb/c-Abl in the negative selection of GC B cells in FccRIIb 232T/T mice. Importantly, our findings indicate potential benefits of up-regulating FccRIIb expression in B cells for treatment of systemic lupus erythematosus.
Fcc receptor IIb (FccRIIb) is a low-affinity Fcc receptor for IgG. The Fc portion of IgG binds to the second Ig domain located near the transmembrane region of FccRIIb proteins (1, 2) . In B cells, FccRIIb is an indispensable inhibitory regulator. FccRIIb-deficient mice exhibit splenomegaly due to expansion of B cells and eventually develop lupus-like disease (3, 4) . Depending on the affinity of antigens to the B cell receptor (BCR), FccRIIb can transduce 2 distinct inhibitory signals upon stimulation of IgG immune complexes (ICs) to block B cell function (5) . When FccRIIb is co-ligated to the BCR, FccRIIb blocks BCR signaling for proliferation and differentiation, and when independently engaged, FccRIIb triggers B cell apoptosis by a c-Abl-dependent mechanism (1, 2, 5) . When the BCR and FccRIIb are co-engaged, the cytoplasmic immunoreceptor tyrosine-based inhibition motif of FccRIIb is phosphorylated by the Lyn kinase, followed by recruitment of the lipid phosphatase SH2 domain-containing inositol-5 0 -phosphatase (SHIP), which hydrolyzes PI(3-5)P 3 to antagonize phosphatidylinositol 3-kinase signals for activation and proliferation of B cells (6) (7) (8) . On the other hand, when the antigen in IgG ICs has low or no affinity for BCRs, FccRIIb can directly trigger apoptosis of B cells via c-Abl kinase (5) . The FccRIIbdependent apoptosis of B cells has been proposed to play a role in the elimination of autoreactive B cells, which emerge as low-affinity B cells in the germinal center (GC) (9) , but evidence from in vivo studies is largely lacking.
The human FccRIIb-I232T polymorphic variant, in which the isoleucine at position 232 of FccRIIb is replaced by threonine, is a risk allele for systemic lupus erythematosus (SLE). The prevalence of FccRIIb-I232T carriers has been reported to be up to 40% of SLE patients in Africans and Southeast Asians (10) (11) (12) . Biochemical and imaging analyses have revealed a decreased association of FccRIIb-232T proteins with lipid microdomains on the plasma membranes, resulting in blocking the association with BCR that results in inhibitory signaling (13) (14) (15) . Nevertheless, people carrying the FccRIIb-232T allele are protected against malaria infection owing to enhanced antibody response (12, 16, 17) . Conversely, these subjects are susceptible to autoimmune diseases, e.g., SLE (12) . Consistent with these findings, the surface expression of wild-type (WT) FccRIIb in memory B cells and plasma cells (PCs) is down-regulated in patients with SLE (18) (19) (20) . Furthermore, a failure to up-regulate FccRIIb expression on GC B cells has been found in lupus-prone mice regardless of their genetic background (21) . These findings strongly suggest a role of FccRIIb in the GC response and raise the question of whether the hypofunctional FccRIIb-232T allele might result in abnormality in the clonal selection of B cells in GCs, particularly in the deletion of low-affinity autoreactive B cells.
The GC is a critical site for antigen-driven selection of GC B cells for differentiation into PCs to generate high-affinity antibodies for protective immunity. In response to antigen, GC B cells first undergo V(D)J gene hypermutation of their BCRs in the dark zone, followed by migration of GC B cells to the adjacent light zone for selection of cells with high affinity to antigen, a critical process known as affinity maturation (22) (23) (24) . Importantly, while high-affinity GC B cells are positively selected for further development into memory B cells and PCs, GC B cells carrying mutated BCRs of low or no antigenic affinity are negatively selected for apoptosis (25, 26) . To investigate the pathogenesis of human lupus associated with the FccRIIb-I232T polymorphism, we generated FccRIIb 232T/T mice to mimic human FccRIIb-I232T carriers. Given that IgG ICs are readily formed after secondary immunization (27, 28) , the surface expression level of FccRIIb in GC B cells is up-regulated (21), and FccRIIb activation can trigger apoptosis of B cells via cAbl (5), we reasoned that the FccRIIb-232T allele with reduced inhibitory function might result in abnormal negative selection of GC B cells. Whether the dysfunction of the FccRIIb-I232T polymorphism is linked to a GC defect is virtually unexplored. In addition, the consequences of abnormal GC reaction in the pathogenesis of autoimmune diseases are incompletely understood. Importantly, new insights into the causal relationship between the FccRIIb-I232T polymorphism and the pathogenesis of SLE may provide valuable implications for therapeutic exploitation of FccRIIb for patients with SLE and perhaps other autoimmune diseases.
MATERIALS AND METHODS
Reagents. Chicken gamma globulin-conjugated NP 20 (NP 20 232T/T mice on a C57BL/6J background were generated at the gene knockout mouse core facility at the Center of Genomic Medicine of National Taiwan University (NTU). The ATT codon of isoleucine 231 in exon 5 of the Fcgr2b gene was mutated to ACT to encode threonine using a recombineering approach. A neo gene cassette flanked with loxP sequences was inserted into the intron 5 region. The targeting vector was then linearized for electroporation into JM8A3 embryonic stem cells (ESCs). Correctly targeted ESC clones were subsequently injected into C57BL/6 blastocysts to produce chimeras. Chimeric males were bred with C57BL/6 females to produce FccRIIb 232I/T mice. To remove the neo cassette, FccRIIb 232I/T mice were crossed with Sox2-Cre mice (Tg(Sox2-cre)1Amc/J), which were kindly provided by Dr. Ming-Ji Fann (National Yang-Ming University, Taipei, Taiwan). Male and female FccRIIb 232I/T mice were bred to generate offspring carrying FccRIIb 232I/I (WT), FccRIIb 232I/T (heterozygote), or FccRIIb 232T/T (homozygote) genotypes for experiments. All mice were maintained in specific pathogen-free conditions at the Center for Laboratory Animals in the College of Medicine of NTU. The protocols of animal use were reviewed, and the experiments were performed according to the guidelines approved by the Institutional Animal Care and Use Committee of the College of Medicine of NTU. Female mice (7-8 weeks old) were immunized with 50 lg NP 20 -CGG per mouse by intraperitoneal injection. Nilotinib (2 mg/kg/day) was administered intraperitoneally once a day on days 7-9 after secondary immunization. Mice were killed the day after the last injection.
Flow cytometric analysis. Mouse splenocytes were stained with FITC-conjugated CD16/32 mAb for 10 minutes at 4°C, followed by addition of an antibody cocktail containing PE-Cy7-conjugated CD19, BV421-conjugated CD138, PerCP-Cy5.5-conjugated CD11b, Alexa Fluor 700-conjugated CD11c, Alexa Fluor 647-conjugated GL-7, and PE-conjugated NP for 20 minutes on ice. To distinguish GC light zone from dark zone B cells, mouse splenocytes were stained with FITC-conjugated CD16/32, APCCy7-conjugated B220, BV605-conjugated CD86, Alexa Fluor 647-conjugated GL-7, BV421-conjugated CXCR4, PE-Cy7-conjugated CD95, and PE-conjugated NP. Splenic follicular helper T (Tfh) cells were stained with the following mAb: APC-Cy7-conjugated B220, Alexa Fluor 647-conjugated CD4, BV421-conjugated PD-1, PE-conjugated CXCR5, FITC-conjugated ICOS, and BV605-conjugated CD69. Bone marrow cells were stained with FITC-conjugated CD16/CD32, BV421-conjugated CD138, PE-Cy7-conjugated CD19, PerCP-Cy5.5-conjugated CD11b, Alexa Fluor 700-conjugated CD11c, and PE-conjugated NP. Dead splenocytes and bone marrow cells were stained with 7-AAD for 5 minutes before being washed. Cells were processed for analysis using a multicolor LSRFortessa cytometer (BD Biosciences). Data were analyzed using FlowJo version 10.
Confocal microscopy. Splenic B cells from 8-week-old WT and FccRIIb 232T/T mice were isolated (>98% purity) using a mouse B lymphocyte enrichment kit (catalog no. 557792; BD Biosciences) according to the manufacturer's instructions. Purified cells (2 9 10 6 /ml) were incubated with rabbit anti-mouse IgM (25 lg/ml) for 10 minutes on ice followed by Cy3-labeled goat anti-rabbit IgG (50 lg/ml) and FITC-labeled cholera toxin B (10 lg/ml), which binds the lipid raft resident protein ganglioside G M1 , for an additional 10 minutes. Cells were then placed on a shaker (200 revolutions per minute) and incubated at 25°C for the indicated times. After a brief wash, cells were immediately fixed with 4% paraformaldehyde for 10 minutes at room temperature before mounting on slides. Images were acquired, analyzed, and quantified using a Zeiss LSM 880 confocal microscope.
Enzyme-linked immunosorbent assay (ELISA). BSA-conjugated NP 7 or BSA-conjugated NP 30 (5 lg/ml) was added to 96-well high bind plates (100 ll/well; Corning) and incubated at 4°C overnight. Mouse serum samples were diluted to detect IgG (1:200,000) and IgM (1:15,000). After blocking and incubation at 4°C overnight, plates were washed, followed by addition of HRPconjugated rabbit anti-mouse IgG (Fcc-specific) (catalog no. 115-035-071; Jackson ImmunoResearch) or goat anti-mouse IgM (lspecific) (catalog no. 115-035-075; Jackson ImmunoResearch) for a 1-hour incubation at room temperature. After washes, plates were developed with tetramethylbenzidine substrate and the reaction was quenched with 2N H 2 SO 4 . Plates were read at an optical density of 450 nm (OD 450 nm ) and OD 570 nm using an ELISA plate reader (BioTek). The reading values of HRP activities were calculated using OD 450 nm minus OD 570 nm . Standard curves of IgM and IgG concentrations were generated using serially diluted samples of mouse reference serum.
Enzyme-linked immunospot (ELISpot) assay. ELISpot assay was performed as previously described (29, 30) , except that BSA-conjugated NP 7 and BSA-conjugated NP 30 were used as the immobilized antigens to capture NP-specific PCs. Briefly, HRP-conjugated goat anti-mouse IgG and IgM were used for detection of PCs. Approximately 2 9 10 4 cells/well and 1.6 9 10 5 cells/well with 2-fold serial dilutions for the detection of IgG and IgM PCs, respectively, were incubated overnight at 37°C. Spots in wells were developed by addition of 50 ll per well of 3-amino-9-ethylcarbazole substrates and incubation for 30 minutes. After washes and complete air dry, plates were scanned to enumerate spots using a CTL S6 universal analyzer (Cellular Technology).
Immunohistochemical examination. Immunohistochemical analysis of mouse spleen sections was performed using standard procedures with Vectastain ABC kits. Deparaffinized sections (4 lm thick) were stained overnight at 4°C with antibodies specific to active caspase 3 or phospho-c-Abl according to the manufacturer's instructions. After washes with phosphate buffered saline (PBS)-Tween (PBS buffer with 0.1% [volume/ volume] Tween 20), sections were incubated with a species-specific antibody conjugated with HRP for 1 hour at ambient temperature. Slides were washed thoroughly, followed by addition of 3,3 0 -diaminobenzidine substrates for development. Sections were counterstained with hematoxylin before mounting. Slides were photographed using an Axioplan 2 light microscope (Zeiss).
Sequence analysis of the V H 186.2 region of BCRs from NP+ GC B cells. Genomic DNA of sorted GC B cells (NP+B220+GL-7+IgG+;~1,000 cells per mouse) was extracted using a QIAamp DNA micro kit (Qiagen). For the amplification of V H 186.2-J H 2 segments, 1 ng of genomic DNA was used as template, and polymerase chain reaction (PCR) products were generated from high-fidelity PrimeStar DNA polymerase (Takara Bio). The PCR primers have been described previously (31): forward primer, 5
0 -AGCTGTATCATGCTCTT CTTGGCA-3 0 and reverse primer, 5 0 -AGATGGAGGCCAGT-GAGGGAC-3 0 (31). Illumina libraries were generated from PCR products using a TruSeq library preparation kit and were sequenced using Illumina MiSeq to generate paired-end reads of 300 nucleotides. Raw sequencing data were aligned to mouse germline V H 186.2 sequences using Burrows-Wheeler aligner and SAMtools (32, 33) . The W33L mutation percentages in first complementarity-determining region sequences were compared with those in WT mice.
Statistical analysis. Bar graphs were plotted and analyzed using GraphPad Prism software version 6.0. Student's unpaired 2-tailed t-test was used for statistical analysis. The ttest was modified by Welch's correction in case of unequal variance. Tukey's test with one-way analysis of variance was used to compare multiple groups. Results are presented as the mean AE SEM. P values less than 0.05 were considered significant.
RESULTS

FccRIIb
232T/T mice exhibit enhanced antibody production with reduced affinity maturation. Because the isoleucine 232 residue of human FccRIIb is conserved in mice (NCBI accession nos. NP_001070657.1 and NP_ 003992.3), we generated a mouse line, termed the FccRIIb 232T/T mouse line, which carries a point mutation of the isoleucine residue at position 231 (232 in humans) replaced by threonine ( Figure 1A ). Consistent with previous findings of live cell imaging (15) , the surface FccRIIb-232T proteins and lipid rafts were neither stably associated nor co-clustered to form cap structures in splenic B cells (see Supplementary Figure 1 , available on the Arthritis & Rheumatology web site at http://onlinelibrary. wiley.com/doi/10.1002/art.40555/abstract).
To investigate GC response, we immunized each WT and FccRIIb 232T/T mouse by intraperitoneal injection with 50 lg of NP 20 -CGG mixed with an equal volume of alum. All mice received a booster injection with the same amount of NP 20 -CGG on day 28 after primary immunization and were killed on day 35, when clonal selection was actively proceeding (24,25) ( Figure 1B) . Serum samples were collected on day 14 and day 35 and tested in ELISA plates coated with either IgG-specific antibodies to detect total serum IgG, NP 30 to detect NP-specific antibodies of all affinities, or NP 7 to detect high-affinity NP-specific antibodies (30, 31) . The serum levels of total IgG were significantly higher in FccRIIb 232T/T mice than in WT mice following both primary immunization (day 14) (P = 0.0035) and secondary immunization (day 35) (P = 0.032) (Figure 2A ).
Fourteen days after the primary immunization, FccRIIb 232T/T mice produced similar levels of highaffinity NP-specific antibodies (P = 0.5033) but more than double the amount of low-affinity NP-specific antibodies compared to WT mice (P < 0.05) ( Figure 2B ). By day 35, seven days after secondary immunization, FccRIIb 232T/T mice produced significantly more highaffinity and low-affinity NP-specific antibodies than WT mice (P < 0.05 for NP 7 ; P < 0.01 for NP 30 ) (Figure 2B) . The ratio of high-affinity to total (low affinity plus high affinity) NP-specific IgG (NP 7 -bound IgG: NP 30 -bound IgG) was lower in the serum of FccRIIb 232T/T mice than in that of WT mice, indicating reduced affinity maturation of antibodies (P < 0.05) ( Figure 2B ). Moreover, sequencing of the NP-specific V H 186.2 region of B cells expressing NP-specific BCRs showed a decreased percentage of W33L replacement, which gives rise to high-affinity BCR variants, in FccRIIb 232T/T mice (P < 0.001) ( Figure 2C ). In addition, we found a trend toward a lower ratio of replacement to silent hypermutation in FccRIIb 232T/T mice mice after secondary immunization. Because affinity maturation was reduced in FccRIIb 232T/T mice compared to WT mice, we investigated whether the elimination of lowaffinity antigen-specific B cells was abnormal in GCs. As shown in Figure 3A , the percentages of splenic CD19+ B cells in lymphocytes were comparable in WT and FccRIIb 232T/T mice. However, the percentage of NP+CD19+ B cells was substantially increased in FccRIIb 232T/T mice compared to WT mice after secondary immunization. Similarly, the percentage of splenic CD19+CD138+ PCs in FccRIIb 232T/T mice was not different from that in WT mice, but the percentage of NP+CD19+CD138+ PCs was significantly increased in FccRIIb 232T/T mice (P < 0.001) ( Figure 3B ). We next used ELISpot assays to quantify the numbers of splenic NP+ PCs. Consistent with an increased level of circulating NP 30 + IgG, a greater number of NP 30 +IgG+ PCs was detected in FccRIIb 232T/T mice than in WT mice (P < 0.05) ( Figure 3C ). Further analysis of splenic NP+IgG+ PCs revealed no significant 232T/T mice. A and B, Serum levels of total IgG (A) and high-affinity NP 7 IgG and total NP 30 IgG (B) in wild-type (WT) mice and FccRIIb 232T/T mice 2 weeks after primary immunization (day 14) (P = 0.0035 for IgG, P = 0.5033 for NP 7 , and P = 0.0469 for NP 30 ) and 1 week after secondary immunization (day 35) (P = 0.032 for IgG, P = 0.0411 for NP 7 , and P = 0.0068 for NP 30 ). In B, the ratios of NP 7 to NP 30 IgG levels in serum on day 14 (P = 0.0427) and day 35 232T/T mice). * = P < 0.05; ** = P < 0.01; *** = P < 0.001. NS = not significant.
differences in the numbers of high-affinity NP 7 + PCs between WT and FccRIIb 232T/T mice. In contrast, compared to WT mice, the numbers of low-affinity IgG+ PCs (NP 30 + PCs minus NP 7 + PCs) increased~3-fold in FccRIIb 232T/T mice (P < 0.05) ( Figure 3C ). These differences were not observed when the numbers of NP+IgM+ PCs were compared between WT and FccRIIb 232T/T mice ( Figure 3D ), suggesting a specific IgG-associated effect through FccRIIb. Of interest, we found that the numbers of low-affinity NP+IgG+ PCs were also significantly increased in heterozygous FccRIIb-232T mice compared to WT mice (see Supplementary Figure 2 , available on the Arthritis & Rheumatology web site at http://onlinelibrary. wiley.com/doi/10.1002/art.40555/abstract). These findings suggest that FccRIIb-232T might impede recruitment of sufficient amounts of WT receptors to reach the threshold 232T/T mice after secondary immunization. A and B, Percentages of CD19+ B cells (P = 0.2846) and NP+CD19+ B cells (P = 0.0007) (A) and percentages of CD19+CD138+ PCs (P = 0.8432) and NP+CD19+CD138+ PCs (P = 0.0009) (B) in splenic lymphocytes from wild-type (WT) mice and FccRIIb 232T/T mice on day 35, analyzed by flow cytometry. C, Splenic total IgG+ PCs (P = 0.0315), high-affinity NP 7 -specific IgG+ PCs (P = 0.4318), total NP 30 -specific IgG+ PCs (P = 0.0168), and low-affinity NP+IgG+ (NP 30 minus NP 7 ) PCs (P = 0.0159) in WT mice and FccRIIb 232T/T mice on day 35, determined using enzymelinked immunospot assays (using 6 9 10 3 cells to detect total PCs and 2. 232T/T mice). Right, Staining for active caspase 3 to detect apoptotic GC B cells in the light zone of GCs (encircled areas) in splenic sections from WT and FccRIIb 232T/T mice. * = P < 0.05; ** = P < 0.01; *** = P < 0.001. NS = not significant.
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mice (P = 0.8622) despite an increased number of NP+ PCs in FccRIIb 232T/T mice ( Figure 3 ). Consistent with increased serum levels of total IgG in FccRIIb 232T/T mice (Figure 2A) , the serum concentrations of IgG1, IgG2a, and IgG3 isotypes were all significantly higher in immunized FccRIIb 232T/T mice than WT mice (P < 0.05) ( Figure 4B) . Similarly, the serum levels of high-affinity (NP 7 )-specific and total NP+ (NP 30 )-specific IgG isotypes remained higher in FccRIIb 232T/T mice than in WT mice ( Figures 4C and D) .
Reduced apoptosis of B cells in GC light zones of immunized FccRIIb 232T/T mice. To further delineate the abnormality of GC response in FccRIIb 232T/T mice, we quantified NP+CD19+GL-7+ GC B cells and found that FccRIIb 232T/T mice exhibited more splenic NP+ GC B cells than WT mice ( Figure 5A ). When GC dark zone (CD86 low CXCR4 high ) and light zone (CD86 high CXCR4 low ) B cells were analyzed and compared, we found a decreased percentage of GC dark zone B cells (P < 0.001) (Figure 5A ) but an increased percentage of GC light zone B cells (P < 0.001) ( Figure 5A ) in FccRIIb 232T/T mice. Moreover, we detected an increase in the size of GCs in splenic sections from immunized FccRIIb 232T/T mice (Figure 5B) . It has been shown that the surface expression of FccRIIb in GC B cells is up-regulated in normal mice (16) . We examined the FccRIIb expression levels in GC B cells and found no significant differences in FccRIIb expression between WT and FccRIIb 232T/T mice either before or after immunization ( Figure 5C ). Because clonal selection of GC B cells occurs primarily in the light zone of GCs (17-22), we next investigated the apoptosis of GC B cells to determine the extent of negative selection of low-affinity B cells after secondary immunization. Consistent with an increase in GC B cell numbers in FccRIIb 232T/T mice, the percentage of dead GC B cells was significantly decreased in these mice (P < 0.05) ( Figure 5D ). Significantly fewer apoptotic GC B cells, which were stained by active caspase 3 mAb, were detected in FccRIIb 232T/T mice after secondary immunization ( Figure 5D ).
Blocking c-Abl activity in WT mice during clonal selection recapitulates the GC phenotype of FccRIIb 232T/T mice. Because FccRIIb is known to mediate apoptosis via c-Abl kinase in response to IgG ICs in B cells (5), we investigated the expression of active c-Abl (p-Y245) proteins in GC B cells. In WT mice, phospho-c-Abl proteins were readily detectable and mainly localized in the light zone of GCs, where affinity maturation and clonal selection occur. In contrast, the levels of phospho-c-Abl proteins were substantially decreased in the GCs of FccRIIb 232T/T mice ( Figure 6A ). It has been reported that the apoptosis of GC B cells peaks during days 7-9 after secondary immunization (34) . Thus, to determine whether c-Abl activity is crucial for FccRIIb to negatively regulate GC B cells, we treated WT mice with nilotinib (2 mg/kg/day) to block c-Abl kinase activity during the peak period when GC B cells undergo apoptosis for selection after secondary immunization. Indeed, the serum titers of NP+ IgG displayed reduced affinity maturation in nilotinib-treated mice (P < 0.05) ( Figure 6B ). Moreover, the number of low-affinity NP+IgG+ PCs (NP 30 PCs minus NP 7 PCs) was significantly increased after c-Abl kinase activity was blocked in WT mice (P < 0.01) ( Figure 6C) . Thus, the findings in antibodies produced from nilotinib-treated WT mice are reminiscent of the GC defect observed in FccRIIb 232T/T mice after secondary immunization (Figures 2 and 3) .
DISCUSSION
In this study, we showed for the first time that compromised inhibitory activity of FccRIIb-232T proteins results in insufficient deletion of low-affinity antigenspecific GC B cells and reduces affinity maturation in clonal selection. Consequently, the resultant increase in low-affinity antigen-specific GC B cells leads to a corresponding increase in low-affinity antigen-specific IgG in circulation in FccRIIb 232T/T mice (Figures 2 and 3 ). Compared to WT mice, the number of GC light zone B cells was increased in FccRIIb 232T/T mice due to a decrease in the apoptosis of GC B cells and in the phosphorylation of c-Abl proteins (Figures 5 and 6 ). Furthermore, administration of nilotinib to WT mice to block c-Abl kinase activity at the peak of apoptosis of GC B cells in clonal selection resulted in reduced affinity maturation reminiscent of the phenotype of immunized FccRIIb 232T/T mice. The involvement of c-Abl in the clonal selection of GC B cells is a novel and important finding. The newly identified, crucial role of FccRIIb in regulating the stringency of affinity maturation by triggering apoptosis to delete lowaffinity GC B cells via c-Abl is illustrated in Figure 6D .
Because FccRIIb 232T/T mice display a higher serum level of high-affinity NP-specific IgG, the reduced inhibition of FccRIIb-232T on BCRs might have the potential to promote the proliferation of GC B cells. Indeed, numbers of GC B cells increased in FccRIIb 232T/T mice after secondary immunization ( Figure 5A) . Nevertheless, the increased number of B cells was largely due to an increase in low-affinity B cells, since no increase in high-affinity IgG+ PCs was observed in FccRIIb 232T/T mice ( Figure 3 ). This leads us to conclude that the retention of low-affinity B cells is more a consequence of insufficient apoptosis rather than insufficient inhibition of proliferation of GC B cells in FccRIIb 232T/T mice. In addition, because low-affinity B cells are intrinsically less competitive than high-affinity cells for antigen stimulation, the increased survival of low-affinity FccRIIb 232T/T GC B cells is positively associated with reduced apoptosis. One important caveat is that low-affinity antigen-specific GC B cells may have a chance to undergo further affinity maturation when the competition with high-affinity B cells becomes reduced in late FccRIIb-232T IMPAIRS GC B CELL SELECTIONGCs (35) . However, in the persistence of FccRIIb-232T dysfunction, repeated immunization generates a new pool of low-affinity B cells, which normally should have been deleted. Consistent with this finding, the serum level of low-affinity antigen-specific IgG and the number of IgG+ PCs remained significantly increased after secondary immunization in FccRIIb 232T/T mice (Figures 2 and 3 ). These findings raise the possibility of undesired consequences of enhanced immune response due to the presence of the FccRIIb-232T allele. For example, lowaffinity memory B cells might persist in peripheral lymphoid organs, and low-affinity PCs emigrated from GCs into circulation might be able to become long-term residents in the bone marrow to secrete low-affinity antibodies (36) . An additional caveat is that because serum NP+ IgG display increasing affinity maturation in WT mice over time but remain reduced in FccRIIb 232T/T mice after primary immunization, the contribution of extrafollicular response to influence the outcome of low-affinity B cells is likely limited (Supplementary Figure 3 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/ 10.1002/art.40555/abstract).
Consistent with previous findings in living cells (14, 15) , FccRIIb-I232T proteins appear to form small raft-associated clusters rather than coalesced caps for signal amplification as compared to receptors in WT mice at 30-60 minutes (see Supplementary Figure 1 , available on the Arthritis & Rheumatology web site at http://online library.wiley.com/doi/10.1002/art.40555/abstract). The resultant diminished recruitment of SHIP to FccRIIb-232T therefore can account for reduced inhibition on B cells in response to IgG ICs. However, mice deficient in the Ship gene show no differences from WT mice in antibody production after immunization with a Tcell-dependent antigen (37) . Nevertheless, when the Ship gene is specifically deleted in B cells, they are indeed more sensitive to antigen activation than WT cells in vitro (38) .
Surprisingly, the number of NP+ GC B cells and the serum level of NP+ IgG decreased markedly after NP-CGG immunization. It appears that hyperactive BCR signaling in SHIP-deficient GC B cells directly induces apoptosis of both low-and high-affinity B cells (38) . Thus, a tightly regulated balance between FccRIIb/SHIP and FccRIIb/c-Abl pathways in response to IgG ICs is crucial for normal outcome of GC reaction. Consistent with this notion, an increased sensitivity to FccRIIb-dependent apoptosis might contribute in part to the GC phenotype in mice with SHIP deficiency in B cells. Indeed, loss of SHIP in DT40 B cells enhances FccRIIb-induced apoptosis (9) . We previously showed that apoptosis of B cells induced by FccRIIb is dependent on c-Abl, but independent of SHIP, suggesting a decisive role of c-Abl when activated (5).
In the GC, low-affinity B cells are outcompeted by high-affinity B cells for antigen stimulation and Tfh cell help, thereby lacking survival advantages (39, 40) . In the present study, we provided evidence of a new role of the FccRIIb/c-Abl signaling pathway to participate in the negative selection of low-affinity B cells. Consistent with our findings, enhancing survival of GC B cells by overexpression of the Bcl-x L gene in mice results in reduced affinity maturation (41) . Similarly, mice overexpressing Bcl-2 show decreased negative selection of GC B cells (42, 43) . These findings indicate that enhanced BCR signaling can increase the survival of low-affinity B cells to avoid negative selection. Whether these low-affinity B cells might have overcome the apoptotic induction from FccRIIb to escape deletion is of interest for future studies. Meanwhile, it has been demonstrated that low-affinity autoreactive B cells are more sensitive to CpG double-stranded DNA-induced differentiation into PCs than high-affinity B cells (44, 45) . Thus, low-affinity autoreactive B cells are able to efficiently expand independent of antigen stimulation if they can escape from elimination in GCs. Because autoreactive B cells are routinely generated in response to a foreign antigen in normal mice, e.g., resulting from host immune response against pathogens (46), low-affinity autoreactive B cells, which are likely generated from time to time, need to be deleted when they emerge in GCs to prevent autoimmunity.
Our findings indicate that in FccRIIb-232T allele carriers, the persistent presence of low-affinity B cells and especially PCs may gradually become a key contributor that puts them at risk of developing autoimmune diseases over time. Reduced surface expression levels of WT FccRIIb in the B cells of SLE patients may result in susceptibility to the presence of low-affinity B cells (18) (19) (20) . Accordingly, because transgenic mice overexpressing Fcgr2b in B cells exhibit reduced SLE disease severity (47) , it will be of interest to investigate whether regimens that up-regulate the surface expression level of FccRIIb-232T proteins to enhance their inhibition can restore competency to negatively regulate low-affinity GC B cells for therapeutic exploitation.
